Related references
Note: Only part of the references are listed.Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen
Bo Wang et al.
MABS (2020)
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Lionel Rouge et al.
SCIENCE (2020)
Binding mechanisms of therapeutic antibodies to human CD20
Anand Kumar et al.
SCIENCE (2020)
How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2+
Ronald P. Taylor et al.
ANTIBODIES (2020)
Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent
Sina Bondza et al.
MABS (2020)
Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces
Juergen Strasser et al.
NANO LETTERS (2019)
Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells
Yang Li et al.
ONCOLOGY LETTERS (2019)
New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies
Saskia Meyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement
Deniz Ugurlar et al.
SCIENCE (2018)
Complement in cancer: untangling an intricate relationship
Edimara S. Reis et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
Venkat Reddy et al.
RHEUMATOLOGY (2017)
CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity
Yu Wang et al.
ONCOLOGY LETTERS (2017)
Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells
Sina Bondza et al.
FRONTIERS IN IMMUNOLOGY (2017)
IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions
Chang-Han Lee et al.
NATURE IMMUNOLOGY (2017)
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells
Patrick J. Engelberts et al.
JOURNAL OF IMMUNOLOGY (2016)
Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells
Margaret A. Lindorfer et al.
MOLECULAR IMMUNOLOGY (2016)
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
Rob N. de Jong et al.
PLOS BIOLOGY (2016)
Activatory and Inhibitory Fcγ Receptors Augment Rituximab-mediated Internalization of CD20 Independent of Signaling via the Cytoplasmic Domain
Andrew T. Vaughan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Macrophages are critical effectors of antibody therapies for cancer
Kipp Weiskopf et al.
MABS (2015)
Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Venkat Reddy et al.
ARTHRITIS & RHEUMATOLOGY (2015)
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wei Wang et al.
FRONTIERS IN IMMUNOLOGY (2015)
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Saskia Meyer et al.
MABS (2014)
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Christoph A. Diebolder et al.
SCIENCE (2014)
CD19 Is a Useful B Cell Marker After Treatment With Rituximab: Comment on the Article by Jones et al
Elena G. Kamburova et al.
ARTHRITIS AND RHEUMATISM (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement
Marcin Okroj et al.
MEDICAL ONCOLOGY (2013)
Rituximab mediates loss of CD19 on B cells in the absence of cell death
Jonathan D. Jones et al.
ARTHRITIS AND RHEUMATISM (2012)
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
Matthew J. Barth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
Frank J. Beurskens et al.
JOURNAL OF IMMUNOLOGY (2012)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
Gerhard Niederfellner et al.
BLOOD (2011)
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
Peter Boross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
Stephen A. Beers et al.
BLOOD (2010)
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Gregory L. Moore et al.
MABS (2010)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Andrew W. Pawluczkowycz et al.
JOURNAL OF IMMUNOLOGY (2009)
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
Clive S. Zent et al.
LEUKEMIA RESEARCH (2008)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
K Takei et al.
LEUKEMIA RESEARCH (2006)
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59
F Ziller et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia
AD Kennedy et al.
JOURNAL OF IMMUNOLOGY (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
JJ Uchida et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
O Manches et al.
BLOOD (2003)
An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab
AD Kennedy et al.
BLOOD (2003)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
WK Weng et al.
BLOOD (2001)
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
